Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI)

7 juli 2020 uppdaterad av: Karagiannidis Efstratios, Aristotle University Of Thessaloniki

Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)

The study aims to assess for the first time, through the application of innovative technologies (micro-CT), important characteristics of aspirated thrombi (such as their volume and their density), which might be linked to certain clinical outcomes, in patients presenting with STEMI and referred for primary Percutaneous Coronary Intervention (PCI). To this end, a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi will be developed. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume and their density will be calculated with the use of micro-CT. Having a better resolution than conventional computed tomography, micro-CT will allow us to create 3D models of aspirated thrombi from a series of x-ray projection images. These 3D models will be further analyzed in order to find the volume and the density of aspirated thrombi. Shape analysis of the surface of aspirated thrombi and potential differences in their structure will also be assessed. Correlation of these variables with clinical parameters and angiographic outcomes will be attempted.

Thus, a risk-stratification model will be developed combining:

  • Clinical and laboratory data,
  • Angiographic parameters,
  • Data regarding the volume, the density and the composition of aspirated thrombi.

This model will enable the stratification of the cardiovascular and cerebrovascular risk of patients and the identification of who will benefit from thrombus aspiration, providing a personalized approach in treating patients with STEMI.

Studieöversikt

Status

Avslutad

Detaljerad beskrivning

Acute myocardial infarction with ST elevation (STEMI) remains one of the leading causes of mortality in developed countries, in spite of the important advances in pharmacological therapy and in mechanical reperfusion therapy. Having an important role in provoking ischemia, thrombus has been studied in many clinical trials and high thrombus burden has been proven to be an independent risk factor for stent thrombosis and for Major Adverse Clinical outcomes. However large randomized controlled trials concerning thrombus aspiration showed controversial results, providing as a whole no evidence of distinct benefits for thrombus aspiration. A possible explanation could be that aspiration was performed as a routine strategy in all of these trials, whereas these patients should be considered as a heterogeneous group and thus they should be risk-stratified. For this reason, it is of paramount importance to classify patients according to the volume of thrombus burden. The currently existing classifications of thrombus burden (the most important being those of Gibson and of Sianos) are based on visual assessment of angiographic characteristics and thus they are not reflecting the volume of the thrombi in actual, absolute numbers.

The main purpose of the study is to develop a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi in patients presenting with STEMI and referred for primary PCI. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume will be calculated with the use of micro-CT. The scanning procedure results into a series of projection images arranged in the form of image stacks which, in turn, are reformed in sections (cross section images) with the use of the NRecon (Bruker, Kontich, Belgium) software, which applies a modified algorithm of backward projection Feldkamp. The resulting sections will be combined to create the 3D models which will be further analyzed to extract useful measurements for the characteristics of the thrombi, such as for the volume and the elative density. Shape analysis on the surface and internal structure of the three-dimensional representations of the specimens will lead to the identification of the important features that can be used to estimate variability within samples and perform clustering for the significant differences between clots. In addition, possible differences in clot internal and external structure (e.g. architecture of the various cell types) will be assessed through the 3D models rendered from the stacks of images The Secondary end points of the study include the examination of the association of the aforementioned variables with the angiographic classification of thrombus burden (according to Sianos), with electrocardiographic and angiographic characteristics suggestive of poor patient prognosis and with major adverse cardiac events during the follow-up period of one year.

This method could become the gold standard for the exact measurement of thrombus burden and could be used in larger, clinically-oriented trials to help stratify patients with thrombus burden according to their risk for adverse outcomes.

Studietyp

Observationell

Inskrivning (Faktisk)

115

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Thessaloníki, Grekland, 54636
        • University General Hospital of Thessaloniki AHEPA

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

consecutive patients presenting with ST elevation myocardial infarction, who undergo primary PCI and thrombus aspiration

Beskrivning

Inclusion Criteria:

  • Patients presenting with symptoms of myocardial ischemia lasting for more than 30 minutes
  • Definite ECG changes indicating STEMI
  • Patients undergoing primary PCI within 12 hours from symptom onset
  • Possibility to perform thrombus aspiration
  • Age>18 years
  • Written informed consent prior to enrolment in the clinical trial

Exclusion Criteria:

  • Treatment with fibrinolytic therapy for qualifying index STEMI event
  • Patients with known intolerance to aspirin, ticagrelor or heparin
  • Patients with active internal bleeding
  • Patients with a recent history of intracranial hemorrhage

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Endast fall
  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
patienter med låg trombbelastning
patienter med den lägre volymen av aspirerade tromber, mätt med mikro-CT
patienter med hög trombbelastning
patienter med den högre volymen av aspirerade tromber, mätt med mikro-CT

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
volume of aspirated thrombus burden
Tidsram: 12 months
The volume of aspirated thrombi will be quantified using micro-CT.
12 months
density of aspirated thrombus burden
Tidsram: 12 months
The density of aspirated thrombi will be quantified using micro-CT.
12 months
MACCE-free survival
Tidsram: 12 months
Time between the date of diagnosis and MACCE during the follow-up period of 12 months. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
association between thrombus volume with factors from patients medical history
Tidsram: 12 months
Potential association of thrombus volume (as assessed using micro-ct) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
association between thrombus density with factors from patients medical history
Tidsram: 12 months
Potential association of thrombus density ( as assessed using micro-CT) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
Correlation of the volume of aspirated thrombus burden with the Sianos' classification of thrombus burden
Tidsram: 12 months
Potential correlation of the volume of aspirated thrombus burden, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored. According to Sianos' classification thrombi are classified in the following categories: G0,G1,G2,G3,G4.
12 months
Correlation of thrombus density with the Sianos' classification of thrombus burden
Tidsram: 12 months
Potential correlation of thrombus density, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.
12 months
association of thrombus volume with electrocardiographic outcomes suggestive of poor patient prognosis
Tidsram: 12 months
Potential association of thrombus volume as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus density with electrocardiographic outcomes suggestive of poor patient prognosis
Tidsram: 12 months
Potential association of thrombus density as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus volume with post-procedural Thrombolysis in Myocardial Infarction(TIMI) flow
Tidsram: 12 months
Potential association of thrombus volume as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus density with post-procedural TIMI flow
Tidsram: 12 months
Potential association of thrombus density as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus volume with myocardial blush grade
Tidsram: 12 months
Potential association of thrombus volume as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus density with myocardial blush grade
Tidsram: 12 months
Potential association of thrombus density as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus volume with distal embolization .
Tidsram: 12 months
Potential association of thrombus volume as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus density with distal embolization .
Tidsram: 12 months
Potential association of thrombus density as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus volume with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Tidsram: 12 months
Potential association of thrombus volume, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months
association of thrombus density with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Tidsram: 12 months
Potential association of thrombus density, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Georgios Sianos, MD,PhD, FESC, Associate Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Huvudutredare: Efstratios Karagiannidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Huvudutredare: Charalambos Karvounis, MD,Phd, Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Huvudutredare: George Giannakoulas, MD,Phd, Assistant Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Huvudutredare: Christos Arvanitidis, Phd, Director of Research, Hellenic Center for Marine Research
  • Huvudutredare: Ioannis Vizirianakis, PharmD, PhD, Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
  • Huvudutredare: James S Michaelson, MD,Phd, Associate Professor, Department of Pathology, Harvard Medical School
  • Huvudutredare: Kleoniki Keklikoglou, MSc, HELLENIC CENTER FOR MARINE RESEARCH
  • Huvudutredare: Ivelin Samra, MD, Head of cardiology department at MHAT"Hadzy Dimityr" Sliven
  • Huvudutredare: Nikolaos Konstantinidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Huvudutredare: Georgios Sofidis, MD,Phd, Aristotle University Of Thessaloniki

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 januari 2018

Primärt slutförande (Faktisk)

7 juli 2020

Avslutad studie (Faktisk)

7 juli 2020

Studieregistreringsdatum

Först inskickad

25 januari 2018

Först inskickad som uppfyllde QC-kriterierna

5 februari 2018

Första postat (Faktisk)

12 februari 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 juli 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

7 juli 2020

Senast verifierad

1 juli 2020

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

Obeslutsam

IPD-planbeskrivning

The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på ST Elevation hjärtinfarkt

3
Prenumerera